{"filings":[{"id":581960,"accession_number":"0001438133-26-000070","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2026-05-21T20:10:03+00:00","items":["3.03","5.02","5.07","9.01"],"status":"ready","headline":"Tandem Diabetes shareholders approve charter amendments and equity plan increase at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved charter amendments to allow removal of directors with or without cause and limit officer liability per DGCL Sections 141(k) and 102(b)(7).","2023 Long-Term Incentive Plan amended to increase authorized shares by 3,260,000, bringing total to 8,862,184 shares.","All nine director nominees elected; Christopher Twomey received 7,034,208 against votes (12.8% of votes cast) but still passed.","Say-on-pay passed with 53,460,747 for, 1,481,027 against.","Ernst & Young ratified as independent auditor for fiscal year ending December 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452724,"accession_number":"0001438133-26-000052","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2026-05-15T11:59:42+00:00","items":["5.02"],"status":"ready","headline":"Tandem Diabetes terminates CCO Mark Novara without cause; last day May 18","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Novara, EVP & Chief Commercial Officer, notified of termination without cause on May 11, 2026.","His last day of employment is scheduled to be May 18, 2026.","Company states its strategy and 2026 goals remain unchanged.","No successor has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92877,"accession_number":"0001438133-26-000048","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Earnings release filed; exhibit not provided in context","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Tandem Diabetes Care filed 8-K for Q1 2026 earnings.","Press release as Exhibit 99.1 was not included in this request.","No specific financial figures, guidance, or segment data available."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":247221000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104068,"accession_number":"0001140361-26-007142","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Tandem Diabetes closes $300M zero-coupon convertible notes due 2032; net proceeds ~$290.7M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $300M aggregate principal of 0.00% Convertible Senior Notes due 2032 (including $35M greenshoe exercised).","Conversion rate initially 27.0362 shares per $1,000 principal (~$36.99 conversion price, 37.5% premium over $26.90).","Net proceeds ~$290.7M; $15.3M used for capped call transactions; remainder for general corporate purposes including M&A.","Capped call transactions reduce dilution on conversion; cap price initially $47.0750 per share (75% premium).","Notes mature March 15, 2032, no regular interest; redemption allowed after March 20, 2029 under conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104067,"accession_number":"0001438133-26-000009","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tandem Diabetes issues Q4/FY2025 earnings release; specific results not provided in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filing reports issuance of press release for quarter and year ended 12/31/2025.","No financial figures (revenue, EPS, guidance) are available from the submitted text.","Exhibit 99.1 press release was referenced but its content was not included in the user message."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":1014736000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120353,"accession_number":"0001438133-25-000237","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Tandem Diabetes amends bylaws with updated advance notice, proxy card, voting rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted Amended and Restated Bylaws on Dec 26, 2025 as part of periodic governance review.","Advance notice provisions updated: stockholder nominees must satisfy Rule 14a-19 requirements; non-compliant nominees disregarded.","White proxy card reserved exclusively for Board; other solicitations must use non-white cards.","Voting standard (plurality for contested, majority for uncontested) determined 10 days before notice mailing.","Board given express authority to cancel, reschedule, or postpone stockholder meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120352,"accession_number":"0001438133-25-000190","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tandem Diabetes appoints Sandra Beaver to board, adds audit and cybersecurity roles","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sandra Beaver joined the board effective Nov. 7, 2025, increasing board size from 8 to 9.","She serves on the Audit and Cybersecurity & Data Privacy committees.","Initial RSU award of 20,242 shares valued at $300K; annual retainer $60K plus committee fees.","Beaver is CFO of Lyra Health; previously CFO of Evolus and held finance roles at Experian and IGT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120351,"accession_number":"0001438133-25-000186","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tandem Diabetes Care issues Q3 2025 results press release; financial details not included in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Earnings press release for quarter ended September 30, 2025 was furnished as Exhibit 99.1.","No specific financial figures (revenue, EPS, segment data) are available from the provided text.","Filing is dated November 6, 2025; press release is referenced as dated September 30, 2025.","Ticker: TNDM; event type: earnings but no results content to summarize."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":724353000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136925,"accession_number":"0001438133-25-000160","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tandem Diabetes receives FDA 510(k) clearance for SteadiSet infusion set for 7-day use","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared SteadiSet infusion set for up to seven days of use; features integrated inserter with hidden needle.","SteadiSet designed for type 1 diabetes patients; will be standalone for t:slim X2 and Tandem Mobi pumps.","Also component of future Tandem Mobi tubeless insulin delivery system; manufacturing scale-up underway.","Company expects to launch after scale-up; financial details in future earnings announcements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136924,"accession_number":"0001438133-25-000155","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q2 2025 earnings release furnished; no specific figures provided in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated June 30, 2025, furnished as Exhibit 99.1, but content not included in the provided filing text.","Item 2.02 reports financial results for quarter ended June 30, 2025, but actual numbers are unavailable for summarization.","Investors should refer to the full press release for specific financial data."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":475100000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154174,"accession_number":"0001438133-25-000112","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["1.01","5.07"],"status":"ready","headline":"Tandem settles patent disputes with Roche, agrees to pay $36M over five years","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves pending patent actions in France and Germany regarding t:slim X2 pump and two EP patents.","Total consideration $36M; initial $8M payment due, remainder in four equal annual installments.","Parties exchange non-exclusive, non-royalty-bearing cross-licenses to insulin delivery system patents for 10 years.","Tandem and Roche mutually release claims and covenant not to sue related to the disputed patents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154173,"accession_number":"0001438133-25-000091","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tandem Diabetes receives CE mark approval for Tandem Mobi with Control-IQ+; EU launch planned by end 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CE mark granted for Tandem Mobi insulin delivery system with Control-IQ+ technology.","Company will pursue in-country registrations and reimbursement in EU markets.","EU commercial launches targeted to begin by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154172,"accession_number":"0001438133-25-000072","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tandem Diabetes receives FDA 510(k) clearance for SteadiSet infusion set (3-day use); plans 7-day submission","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared SteadiSet infusion set for up to 3 days of use; submission by subsidiary CapBio.","SteadiSet features integrated inserter with hidden needle for one-handed insertion; for adults with Type 1 diabetes.","Tandem intends to submit separate 510(k) to extend use to up to 7 days; commercial activities delayed until clearance.","No immediate revenue impact; commercial launch deferred pending 7-day clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154171,"accession_number":"0001438133-25-000068","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tandem Diabetes Care files Q1 2025 results; no financial details in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["8-K filed April 30, 2025 announcing Q1 2025 financial results.","Press release is referenced as Exhibit 99.1 but not included in provided text.","No specific revenue, EPS, or other operational data available from filing.","Ticker TNDM; event type is earnings but no figures to assess."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":234422000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172774,"accession_number":"0001438133-25-000035","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tandem Diabetes Care releases Q4/FY2024 earnings; financial figures not provided in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company issued press release on February 26, 2025 for Q4 and full year 2024 results.","No specific financial data (revenue, EPS, etc.) is available in the 8-K excerpt; exhibit 99.1 is not fully included.","Refer to the full press release for detailed results."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":940203000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189791,"accession_number":"0001438133-24-000200","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tandem Diabetes reports Q3 2024 results; no details in furnished text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filing states a press release was issued for Q3 ended September 30, 2024.","Press release text (Exhibit 99.1) was not included in the provided filing.","No specific financial figures, guidance, or operational metrics are available.","Investors should refer to the original press release for actual results."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":657555000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206299,"accession_number":"0001438133-24-000176","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tandem Diabetes Care reports Q2 2024 results via press release (exhibit text not provided)","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filed 8-K indicating a press release was issued on Aug 1, 2024 for Q2 ended June 30, 2024.","Exhibit 99.1 containing the press release was not provided in the input; specific financial figures unavailable.","Investors should refer to the actual press release for detailed results."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":413584000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223391,"accession_number":"0001438133-24-000166","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tandem Diabetes appoints Jean-Claude Kyrillos as EVP, COO effective June 21, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kyrillos previously served as President of Diagnostics & Digital Solutions at Envista Holdings and held senior roles at Qualcomm Life, BD, and ResMed.","Annual base salary set at $450,203.73; target bonus of 60% of base salary (0-200% payout range) under Cash Bonus Plan.","Target long-term incentive of 400% of base salary in RSUs under the 2023 Long-Term Incentive Plan.","Severance agreement provides 18 months base salary continuation and full equity acceleration upon qualifying termination within change-of-control window.","Kyrillos holds a BA from Colgate University and an MBA from Harvard Business School."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223390,"accession_number":"0001438133-24-000158","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Tandem and Dexcom amend agreements to integrate Sigi pump with G7 CGM for five years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On May 22, 2024, Tandem and Dexcom entered into two amended and restated agreements.","The Development Agreement covers integration of Tandem's Sigi insulin pump with Dexcom's G7 CGM.","Both agreements extend the term to five years and amend definitions and commercial terms.","The Commercialization Agreement addresses the sale and support of the integrated systems.","Original agreements were signed November 2020; new deals update device scope and conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223389,"accession_number":"0001438133-24-000118","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Tandem Diabetes stockholders approve 3M-share increases to ESPP and LTIP at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected all 9 director nominees; highest vote count for John Sheridan (50.3M for).","Approved amendment to 2013 ESPP to increase authorized shares by 3,000,000; 50.4M for, 117,501 against.","Approved amendment to 2023 LTIP to increase authorized shares by 3,000,000; 47.6M for, 3.0M against.","Advisory say-on-pay approved: 47.9M for, 2.3M against, 299,108 abstain.","Ratified Ernst & Young as independent auditor for FY 2024: 53.2M for, 1.4M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223388,"accession_number":"0001438133-24-000088","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Tandem obtains Health Canada approval for Trurapi U-100 compatibility with t:slim X2 pump","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["Health Canada approved adding Trurapi U-100 to compatible insulins list for t:slim X2 with Control-IQ in Canada.","Amended distributor agreement with Unomedical extends term and revises definitions, manufacturing, and purchase terms.","Amendment details to be filed in Q2 2024 10-Q; no financial impact disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223387,"accession_number":"0001438133-24-000085","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tandem Diabetes Care reports Q1 2024 results; specific figures not provided in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated May 2, 2024 covers quarter ended March 31, 2024.","The 8-K body does not include financial data; full exhibit text was not available.","Investors should consult the actual press release for EPS, revenue, and guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":191674000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223386,"accession_number":"0001438133-24-000047","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA clears Tandem Mobi insulin pump for pediatric use ages 2+","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared Tandem Mobi insulin pump for expanded pediatric indication in individuals two years and older.","Clearance was granted via 510(k) application on March 21, 2024.","Indication expansion broadens Tandem's addressable patient population beyond prior adult-only use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242844,"accession_number":"0001438133-24-000042","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Tandem Diabetes Care issues $316.25M convertible notes, repurchases existing 2025 notes and common stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $316.25M aggregate principal amount of 1.50% Convertible Senior Notes due 2029, including full exercise of initial purchasers' option for additional $41.25M.","Used $246.1M of net proceeds to repurchase $246.7M of its 1.50% Convertible Senior Notes due 2025 in privately negotiated transactions.","Used $30.0M to repurchase approximately 1.1 million shares of common stock at $27.105 per share from note purchasers.","Entered capped call transactions with initial purchasers to reduce potential dilution upon conversion, with initial cap price of $42.0128 per share.","Net proceeds were approximately $306.4M after deducting discounts, commissions, and capped call costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242843,"accession_number":"0001438133-24-000026","cik":1438133,"company_name":"TANDEM DIABETES CARE INC","ticker":"TNDM","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tandem Diabetes reports Q4/FY2023 results; detailed metrics not available in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release furnished as Exhibit 99.1 contains financial results for quarter and year ended Dec 31, 2023.","No specific figures (revenue, EPS, guidance) are included in the 8-K body or the provided excerpt.","Investors should refer to the full press release for detailed financial data and management commentary.","The filing is furnished under Item 2.02 and is not deemed filed for SEC purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":747718000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1034789135.9176788,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}